DIFFERENT LIKELIHOOD OF ACHIEVING SVR ON A TELAPREVIR-CONTAINING REGIMEN AMONG NULL RESPONDERS, PARTIAL RESPONDERS AND RELAPSERS IRRESPECTIVE OF SIMILAR RESPONSESAFTER A PEGINTERFERON/RIBAVIRIN 4-WEEK LEAD-IN PHASE: REALIZE STUDY SUBANALYSIS: "When examining this population of TVR-treated patients as a whole, there was a clear relationship between Week 4 response and SVR rates"

Conference Reports for NATAP

Presented at the 22nd Conference of the Asian Pacific Association for the Study of the Liver (APASL)
Taipei, Taiwan
February 16-19, 2012

Back


DIFFERENT LIKELIHOOD OF ACHIEVING SVR ON A TELAPREVIR-CONTAINING REGIMEN AMONG NULL RESPONDERS, PARTIAL RESPONDERS AND RELAPSERS IRRESPECTIVE OF SIMILAR RESPONSESAFTER A PEGINTERFERON/RIBAVIRIN 4-WEEK LEAD-IN PHASE: REALIZE STUDY SUBANALYSIS: "When examining this population of TVR-treated patients as a whole, there was a clear relationship between Week 4 response and SVR rates"

	Reported by Jules Levin Presented at the 22nd Conference of the Asian Pacific Association for the Study of the Liver (APASL), Taipei, Taiwan, February 16-19, 2012 Graham R Foster1, Stuart Roberts2, Stanislas Pol3, Pietro Andreone4, Eric J Lawitz5, Zobair M Younossi6, Sandra De Meyer7, Don Luo8, Gaston Picchio8, Stefan Zeuzem9 1Queen Mary University of London, Institute of Cell and Molecular Science, London, United Kingdom; 2Department of Gastroenterology, Alfred Hospital, Melbourne, VIC, Australia; 3Assistance Publique-Hopitaux de Paris, Cochin Hospital, Paris, France; 4 Universita di Bologna, Bologna, Italy; 5Alamo Medical Research, San Antonio, TX, USA; 6Center for Liver Diseases and Department of Medicine, Inova Fairfax Hospital, Falls Church, VA, USA; 7Janssen Infectious Diseases BVBA, Beerse, Belgium; 8Janssen Research & Development, Titusville, NJ, USA; 9Johann Wolfgang Goethe University Medical Center, Frankfurt am Main, Germany "Since prior response data may not be available for all patients in clinical practice, we also calculated overall SVR rates according to Week 4 response in the LI T12/PR48 arm (Figure 3a). When examining this population of TVR-treated patients as a whole, there was a clear relationship between Week 4 response and SVR rates" In the present analysis, we aimed to determine if refining the Week 4 < or ≥1 log10 HCV RNA response categories impacts SVR with TVR-based treatment in previously treated patients. Therefore we conducted an analysis using smaller intervals of HCV RNA response at Week 4 in the PR and the LI TVR plus PR arms. Patients in the LI T12/PR48 and PR48 arms were categorized according to their HCV RNA reduction after 4 weeks of PR. Week 4 response groups were: 0 to <0.5, ≥0.5 to <1.0, ≥1.0 to <1.5, ≥1.5 to <2.0, or ≥2.0 log10 decrease in HCV RNA. These 0.5 log10 intervals are greater than the assays' coefficient of variation (0.2 log10). · SVR rates by Week 4 HCV RNA response were analyzed for patients in each prior response category.